Focusing on Engineering Cells to Create a New Class of Medicines.
- Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing
- Brings together a portfolio of potential medicines and technologies
- Led by Steve Harr, M.D. as CEO and Hans Bishop as Executive Chairman